JUPITER, Fla., July 15, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, today announced initiation of enrollment for its Phase 1 clinical study of CYT-108, a recombinant variant of the alpha-2-macroglobulin blood serum protein, targeting proteases responsible for cartilage degradation in osteoarthritis (OA). CYT-108 was engineered for increased…

Top-line results from Phase 1 study expected in second quarter of 2025 JUPITER, Fla., Sept. 6, 2024 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing biologic therapies for inflammatory musculoskeletal conditions, today announced completion of enrollment for their Phase 1 clinical study of CYT-108, a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor, as…

– No adverse events reported; CYT-108 progressing as a potential disease-modifying therapy for osteoarthritis – JUPITER, Fla., Jan. 21, 2025 /PRNewswire/ -- Cytonics Corporation, a private biotechnology company developing cutting-edge biologic therapies for musculoskeletal conditions, today announced that the first nine patients in its Phase 1 clinical trial evaluating CYT-108 as a therapy for osteoarthritis have…

Cytonics Seeks $24 million to pursue FDA Phase 2 Clinical Study of CYT-108, the Company's Novel Therapy for Osteoarthritis JUPITER, Fla., March 25, 2025 /PRNewswire/ -- Cytonics today announced that it is launching an offering of securities through the use of an offering statement that has been qualified by the Securities and Exchange Commission. Cytonics has partnered…